Global Vaccine Contract Manufacturing Market Outlook and Forecast 2021-2026: Vaccination Programs For COVID-19 - Vaccine Pipeline Boosting Demand - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Apr 19, 2021--
The “Vaccine Contract Manufacturing Market - Global Outlook and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering.
The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx 13% during the period 2020-2026.
The global vaccine contract manufacturing market has experienced radical transformations after the outbreak of the COVID-19 pandemic, which has been a massive health catastrophe.
Vaccine CMOs have gained significant attention as the virus starts spreading far and wide. A new era of vaccine and biological drug development has prevailed since the advent of the COVID-19 virus. The global pandemic has fueled vaccine innovations with the rapid acceleration of RNA-based COVID vaccines. Contract manufacturing companies are working to increase the availability of COVID-19 vaccines across the globe.
The vaccine manufacturing landscape has changed dramatically over few decades. Almost three-fourths of pharma and biotech companies have entered into mergers and agreements with contract manufacturers to develop COVID-19 vaccines. Outsourcing has gained high significance as it offers significant advantages such as end-to-end manufacturing solutions and expertise in vaccine manufacturing.
A high level of capital expenditure combined with complexity for manufacturing has limited the entry of new players. With maturing pipelines of vaccine products, biotech companies face decisions to partner with existing manufacturers or contract manufacturers or develop in-house manufacturing capabilities.
INSIGHTS BY GEOGRAPHY
North America has the most widespread contract manufacturing organizations, with nearly 40 CMOs present at several US locations. The US accounted for over 90% of the North American vaccine contract manufacturing market share. The increasing trend of outsourcing is benefitting contract manufacturers in the region. Regulations related to vaccine manufacturing, especially in the US and Canada, are boosting the market growth. The prevalence of infectious diseases and the increasing number of deaths due to vaccine-preventable diseases has increased the need for manufacturing.
Europe accounted for the second-highest share of 26% in the vaccine contract manufacturing market in 2020. The increasing elderly population, prevalence of bacterial and viral infections, increasing demand of new vaccinations, and expanding biopharma and biotech industry are major factors contributing to the growth of contract manufacturing in the Europe region.
APAC witnesses growing market demand mainly due to a large and growing population which increases the access to vaccines. In APAC, various opportunities associated with the growing vaccine pipeline, rise in outsourcing of vaccine manufacturing services, implementation of novel and innovative technologies are expected to have a significant influence on the future of the vaccine contract manufacturing market.
INSIGHTS BY VENDORS
Ajinomoto BioPharma, Albany Molecular Research Institute, Catalent, Cytovance Biologics, Emergent Biosolutions, Fujifilm Diosynth Biotechnologies, and GlaxoSmithKline are a few vendors accounting for the global vaccine contract manufacturing market share.
Established players are entering into strategic alliances and co-marketing agreements to elevate the market competitiveness and penetration. They also make long-term relationships with distributors and suppliers for scale-up production and expand geographical presence in the market.
North America offers a high quantity of contract manufacturing services. Europe and APAC have a few prominent players and several small and mid-sized vendors. Emerging economies, including China, India, Brazil, and Mexico, are likely to offer significant growth opportunities for vendors.
Vaccine contract manufacturing companies in India are show promise as the two biopharmaceutical companies - Serum Institute of India and Bharat Biotech- have also received emergency approvals for their serums.
Market Opportunities & Trends
- Global Vaccination Programs For COVID-19
- Manufacturers’ Focus On Scale-Up Vaccine Production
- Growing Agreements Between Vaccine Developers And Contract Manufacturers
- Vaccine Pipeline Boosting The Demand For Contract Manufacturing
Market Growth Enablers
- Favorable Patient Demographics & Growing Vaccinations Of Newborns And Children
- Effect Of Epidemics & Pandemics On Vaccine Development
- Cost-Effective And Time-Saving Services Of Contract Manufacturers
- High Costs and Stockout Issues Of Vaccines
- Lack Of Storage Infrastructure & Limitations Associated With Supply Chain
- Vaccination Concerns In Low And Middle Income Countries
KEY QUESTIONS ANSWERED:
- How big is the vaccine contract manufacturing market?
- Which segment is likely to generate the largest revenue during the forecast period?
- Which region has the largest number of vaccine manufacturers?
- Who are the top vaccine manufacturers?
- How has COVID-19 pandemic affected contract manufacturing companies?
- What limitations are associated with the supply of COVID-19 vaccines for CMOs?
- Ajinomoto Bio-Pharma
- Albany Molecular Research (AMRI)
- Cytovance Biologics
- Emergent BioSolutions
- IDT Biologika
- Merck KGaA
- Serum Institute of India
- Siegfried Holding
Other Prominent Vendors
- Cobra Biologics
- Baxter BioPharma Solutions
- Goodwin Biotechnology
- KBI Biopharma
- Bavarian Nordic
- Charles River Laboratories
- Boehringer Ingelheim
- Samsung Biologics
- Meridian Life Science
- Wacker Biotech B.V
- Jubilant HollisterStier
- Kemwell Biopharma
- Northway Biotech
- Midas Pharma
- Pharmaceutics International Inc. (Pii)
- Singota Solutions
- Thermo Fisher Scientific
- Kaneka Eurogentec
- Richter-Helm BioLogics
- Ology Bioservices
- Corden Pharma
- Cerbios Pharma
- BSP Pharmaceuticals
- JOINN Biologics
- Eurofins Scientific
- Esco Aster
- Genovior Biotech
- AGC Biologics
- Amaran Biotech
- Eden Biologics
- Cell Culture Company
- Taron Solutions
- Axcellerate Pharma
- WuXi Biologics
- Therapure Biopharma
For more information about this report visit https://www.researchandmarkets.com/r/4kvaf4
View source version on businesswire.com:https://www.businesswire.com/news/home/20210419005520/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 04/19/2021 08:58 AM/DISC: 04/19/2021 08:58 AM